Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (21)

2024

  1. Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

    Clinical and Translational Oncology

2022

  1. Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study

    Journal of Personalized Medicine, Vol. 12, Núm. 11

2021

  1. Epithelial mesenchymal transition and immune response in metaplastic breast carcinoma

    International Journal of Molecular Sciences, Vol. 22, Núm. 14

2020

  1. Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences

    American Journal of Surgical Pathology, Vol. 44, Núm. 5, pp. 649-656

  2. Molecular features of metaplastic breast carcinoma: An infrequent subtype of triple negative breast carcinoma

    Cancers, Vol. 12, Núm. 7, pp. 1-13

2018

  1. Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2018), 20, 3, (274-285), 10.1007/s12094-017-1719-x)

    Clinical and Translational Oncology

  2. Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia

  3. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 20, Núm. 3, pp. 274-285

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer

    Journal of Pathology, Vol. 241, Núm. 4, pp. 475-487

2016

  1. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

    Oncotarget, Vol. 7, Núm. 35, pp. 56295-56308

2013

  1. Fe de errores a «Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon»

    Revista Espanola de Patologia

  2. GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012

    Clinical and Translational Oncology, Vol. 15, Núm. 7, pp. 509-525

2012

  1. Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease

    Molecular and Cellular Endocrinology, Vol. 358, Núm. 2, pp. 244-255

  2. Recomendaciones para la determinación de mutaciones de K-RAS en cáncer de colon

    Revista Espanola de Patologia

  3. The EMT signaling pathways in endometrial carcinoma

    Clinical and Translational Oncology, Vol. 14, Núm. 10, pp. 715-720

2011

  1. Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico

    Revista Espanola de Patologia, Vol. 44, Núm. 1, pp. 32-48

  2. Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma

    Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 636-651

2009

  1. Guidelines for HER2 testing in breast cancer. A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 42, Núm. 1, pp. 3-16

2006

  1. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

    Nature Genetics, Vol. 38, Núm. 5, pp. 566-569